AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 5, 2021
29864_dirs_2021-02-05_b2679bab-aa51-4905-a18b-c738743e6792.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-03
Reporting Person: Parini Michael (EVP, Chief Adm, Leg & BD Off)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-03 | Common Stock | A | 8438 | $0.00 | Acquired | 35276 | Direct |
| 2021-02-03 | Common Stock | A | 10324 | $0.00 | Acquired | 45600 | Direct |
| 2021-02-03 | Common Stock | A | 11627 | $0.00 | Acquired | 57227 | Direct |
| 2021-02-03 | Common Stock | M | 400 | $86.52 | Acquired | 57627 | Direct |
| 2021-02-03 | Common Stock | S | 200 | $215.52 | Disposed | 57427 | Direct |
| 2021-02-03 | Common Stock | S | 100 | $217.00 | Disposed | 57327 | Direct |
| 2021-02-03 | Common Stock | S | 100 | $218.20 | Disposed | 57227 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | Stock Option (Right to buy) | $86.52 | M | 400 | Disposed | 2027-02-02 | Common Stock (400) | Direct |
Footnotes
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.
F3: Restricted stock unit award that vests in installments beginning on 02/17/2022.
F4: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F5: Open market sales reported on this line occurred at a weighted average price of $215.52 (range $215.47 to $215.58).
F6: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F7: Fully vested.